CatSci Ltd are pleased to announce that we have won the International Business of the Year award at the 2022 Cardiff Business Awards.
Winning this accolade is another incredible achievement for CatSci and reflects the success of our innovative internationalisation strategy. CatSci’s purpose is and always has been to get new medicines into the hands of patients in need, and we are proud to be supporting our global customers in delivering their best-in-class therapeutics.
The International Business of the Year Award reflects our decades of experience in successfully delivering worldwide CMC development projects along with our customer-centric focus and highly qualified scientific experts. As a UK-based company in the competitive and dynamic pharmaceutical marketplace, we work with 13 countries across the globe, and we’re looking to further increase that in 2023. We are excited for what the future holds for CatSci as we continue with our strategic expansion plans, including the growth of our capabilities, work force, and laboratories. Earlier this year, we received a significant investment from Keensight Capital to facilitate our ambitious growth plans. We also recently announced that we are investing into the development of our oligonucleotide capability, an emerging and innovative modality that offers opportunities to treat rare and previously unmet patients’ needs.
It is an honour to win the Cardiff Business Awards International Business of the Year award; it is the latest of many achievements in what has been a hugely successful and exciting year for us. Along with our significant investment, we also won the prestigious Queen’s Award for Enterprise: International Trade 2022, and surpassed our 100th employee. We are excited to see what the future holds for CatSci as we continue with our mission to break down the silos in drug development to accelerate the delivery of life-changing medicines to patients in need.
